News that BriaCell’s Bria-IMT regimen shows increased survival benefit for breast cancer patients has sent its stock price skyrocketing. Can it advance further?
Investors rewarded the company’s efforts by sending BriaCell Therapeutics stock price skyrocketing, doubling in less than 24 hours. BriaCell has over 7.5 million shares outstanding and is closely monitored by investors in the immunotherapy technology for progress made against cancerous tumours.
BriaCell Therapeutics stock price traded around $3/share, a penny-stock to many willing to speculate on the success of its medical research. As the news that transpired this week shows, the potential for outstanding growth exists, as the company is involved in multiple research tasks.
For now it was Bria-IMT, but BriaCell has other milestones to consider – for example, Bria-OTS is expected to be authorised by the FDA in the third quarter of the year, and during 2022 the pre-registration study data should be available.
BriaCell’s market capitalisation just doubled this week, exceeding $54 million. If the price holds near the vicinity of $6 in the period ahead, the positive results should attract more interest from medium to long-term investors.
Where Can I Buy BriaCell Therapeutics (NASDAQ:BCTX) Stock?
eToro is trusted by millions of customers around the globe and has been one of the leaders in the fintech industry for over a decade. Offering its services in over one hundred countries, eToro strives to offer its customers security when it comes to finding the trading account, as well as privacy.
Capital offers zero commission and no hidden fees to its customers as well as constant updates on the latest economic and market news. The one-click trading experience with over 3,000 markets makes it one of the most competitive brokers in the industry.
What is BriaCell Therapeutics?
BriaCell Therapeutics Corp., or simply BriaCell, is a clinical-stage immunotherapy company with corporate offices in both Canada and the United States. One of its leading drug candidates called Bria-IMT is responsible for increased survival benefit in third-line advanced breast cancer.